ELISpot and FluoroSpot Assay Market Top Players - Oxford Immunotec (UK), Cellular Technology Limited (US), Mabtech (Sweden), Becton, Dickinson and Company (US).

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ELISpot and FluoroSpot Assay Market- (By Product (Assay Kits (Assay Kits by Technique(ELISpot Assay Kits, FluroSpot Assay Kits), Assay Kits by Utility (Diagnostic Kits, Research Kits), Assay Kits by Analyte (T-cell-based kits, B-cell-based kits, Other analytic kits), Analyzers, Ancillary products), By Application (Diagnostic Applications (Infectious Diseases, Transplants), Research Applications (Vaccine Development, Clinical Trials, Cancer Research)), By End-User (Hospitals & Clinical Labs, Research Institutes, Biopharmaceutical Companies and CROs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global ELISpot and FluoroSpot Assay Market is valued at US$ 276.18 Mn in 2022, and it is expected to reach US$ 512.39 Mn by 2031, with a CAGR of 7.2% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2000

The increasing prevalence of chronic diseases, including cancer and autoimmune disorders, is a key factor driving the growth of the Enzyme-Linked Immunospot (ELISPOT) and Fluorospot assay market. These assays play a critical role in the early diagnosis of diseases, monitoring disease progression, and evaluating the effectiveness of medical treatments. For instance, the National Cancer Institute has advised against the use of ELISPOT tests for detecting immune responses to cancer antigens in therapeutic studies. Additionally, the rising incidence of infectious diseases such as Human Immunodeficiency Virus (HIV) and tuberculosis is further fueling demand for these assays. ELISPOT and Fluorospot tests are valuable tools for identifying disease-specific biomarkers and monitoring immune responses to infectious pathogens, enhancing their relevance in clinical research and healthcare management.

List of Prominent Players in the ELISpot and FluoroSpot Assay Market:
• Oxford Immunotec (UK)
• Cellular Technology Limited (US)
• Mabtech (Sweden)
• Becton Dickinson and Company (US)
• Abcam plc. (UK)
• Bio-Techne. (US)
• Mikrogen Diagnostik (Germany)
• Autoimmun Diagnostika GmbH (Germany)
• U-CyTech (Netherlands)
• Medix Biochemica (Finland)
• Merck KGaA (Germany)
• Bio-Sys GmbH (Germany)
• Anogen-Yes Biotech Laboratories Ltd (Canada)
• Abnova Corporation (Taiwan)
• Biorbyt Ltd (UK),
• Tokyo Chemical Industry Co., Ltd. (Japan),
• MP BIOMEDICALS. (US),
• BOC Sciences. (US),
• ZenBio, Inc (US)
• Jackson ImmunoResearch Inc (US),
• Krishgen Biosystems. (India)
• NATIONAL ANALYTICAL CORPORATION (India),
• STEMCELL Technologies Inc. (Canada),
• SERVA Electrophoresis GmbH (Germany),
• IST Scitific LTD (England).

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
Manufacturers are increasingly prioritizing strategic acquisitions, agreements, and collaborations with regional and domestic businesses to meet the growing demand for ELISpot and FluoroSpot assay diagnostics in emerging markets. For example, Siemens Healthineers (Germany) partnered with UNICEF (United States) in February 2022 to strengthen healthcare systems in Sub-Saharan Africa by improving access to diagnostics and treatment. Regulatory policies in the Asia Pacific region are more flexible and business-friendly compared to North American and European markets due to less stringent regulatory frameworks and data requirements. Furthermore, intensifying competition in established markets is prompting ELISpot and FluoroSpot assay manufacturers to shift their focus toward expanding opportunities in the Asia Pacific and Latin America.

Challenges:
Intracellular cytokine staining (ICS), followed by flow cytometry, remains the most widely used technology for measuring cytokine co-expression cells, posing a competitive challenge for FluoroSpot assays, which are relatively new but serve a similar purpose. While FluoroSpot assays offer higher sensitivity than ICS, ICS demonstrates stronger performance, particularly in the accurate detection of fluorescent spots-a challenge due to overlapping detection wavelengths of different fluorescent dyes. To address this, several market players are enhancing their detection technologies. For instance, Mabtech AB introduced the IRIS analyzer, which leverages RawSpot technology for improved spot detection accuracy.

Regional Trends:
North America is expected to lead the ELISpot and FluoroSpot assay market over the forecast period, driven by the increasing prevalence of cancer and infectious diseases. According to the American Cancer Society's Cancer Statistics 2022, approximately 1,918,030 new cancer cases were projected in the United States in 2022, including breast cancer, leukemia, and lymphoma. Additionally, research published by the American Academy of Pediatrics in March 2022 indicated that over one million individuals in the United States are affected by chronic hepatitis B infections, which can lead to chronic conditions such as liver cancer. This rising disease burden is expected to increase vaccination demand and drive the adoption of ELISpot assays, which are highly effective in infectious disease research.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2000

Recent Developments:
• In Mar 2023, The T-Cell Select reagent kit from Oxford Immunotec, which is designed for in vitro diagnostic (IVD) use by accredited laboratories using the T-SPOT.TB test workflow, has received approval from the U.S. Food and Drug Administration (FDA) for the use of two additional cell isolation tools.
• In Mar 2022, Medix Biochemica launched a new brand to show how its recent acquisitions have made its services more exciting and how committed it is to the in vitro diagnostics (IVD) business. Medix Biochemica became the best IVD raw materials seller because of how quickly it grew.

Segmentation of ELISpot and FluoroSpot Assay Market-
By Product-
• Assay Kits
o Assay Kits by Technique
 ELISpot Assay Kits
 FluroSpot Assay Kits
o Assay Kits by Utility
 Diagnostic Kits
 Research Kits
o Assay Kits by Analyte
 T-cell-based kits
 B-cell-based kits
 Other analytic kits
• Analyzers
• Ancillary products
By Application-
• Diagnostic Applications
o Infectious Diseases
o Transplants
• Research Applications
o Vaccine Development
o Clinical Trials
o Cancer Research
By End-User-
• Hospitals & Clinical Labs
• Research Institutes
• Biopharmaceutical Companies and CROs
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.